This page shows the latest Opioid analgesic news and features for those working in and with pharma, biotech and healthcare.
Verdict closely follows rejection of Nektar’s opioid analgesic. The FDA’s Anesthetic and Analgesic Committee has rejected yet another opioid drug – this time Intellipharmaceutics’ extended-release oxycodone tablet Aximiris. ... Despite finding
High levels of euphoric side-effects from opioid medications have lead to abuse and addiction, which has caused a healthcare crisis to erupt across the US. ... Although the rejection is a blow to Nektar, the opioid painkiller had already been somewhat
Opioid product was focus of racketeering charges. Insys Therapeutics has been given the green light to sell its Subsys opioid product – the focus of racketeering charges that forced the company to ... Subsys is a sublingual spray formulation of fentanyl
Almost forgotten among the interest in Nektar’s immuno-oncology pipeline – which also includes three other candidates in clinical trials – is NKTR-181, a first-in-class, abuse-deterrent opioid analgesic ... The drug promises to deliver pain relief
The painkiller was first approved in 2006 to manage moderate-to-sever pain when a continuous, around-the-clock opioid analgesic was needed for an extended period of time, but an ... abuse.”. Opioid overdoses killed 33, 000 Americans in 2015 - with half
Purdue Pharma has expanded its portfolio of opioid analgesic drugs following FDA approval of Hysingla ER, a once-daily product designed to resist abuse. ... The new product will compete in the marketplace against products such as Zogenix' 12-hour Zohydro
More from news
Approximately 1 fully matching, plus 13 partially matching documents found.
Hello. We are the Total Health creative agency. It’s our collective mix of talent that gets us to truly different...